Literature DB >> 18762861

A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years.

Hideko Nakahara1, Toru Mima, Naoko Yoshio-Hoshino, Masato Matsushita, Jun Hashimoto, Norihiro Nishimoto.   

Abstract

Interleukin-6 overproduction is pathologically involved in adult onset Still's disease (AOSD). We successfully treated a man with refractory AOSD utilizing tocilizumab. Tocilizumab was discontinued after 15 doses due to intestinal bleeding, but the efficacy was sustained over 21 months. Tocilizumab was readministered safely upon recurrence and showed similar efficacy over 6 years. Corticosteroid and NSAIDs could be discontinued and intestinal bleeding was no more observed. Tocilizumab can be a therapeutic option for AOSD.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18762861     DOI： 10.1007/s10165-008-0116-2

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN： 1439-7595            Impact factor:   3.023


  16 in total

Review 1.  A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature.

Authors:  Katja Perdan-Pirkmajer; Sonja Praprotnik; Matija Tomšič
Journal:  Clin Rheumatol       Date:  2010-08-24       Impact factor: 2.980

Review 2.  Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review.

Authors:  Ryota Sakai; Hayato Nagasawa; Eiko Nishi; Ayumi Okuyama; Hirofumi Takei; Takahiko Kurasawa; Tsuneo Kondo; Koji Nishimura; Yuichiro Shirai; Tatsuya Ito; Hideto Kameda; Tsutomu Takeuchi; Koichi Amano
Journal:  Clin Rheumatol       Date:  2012-01-04       Impact factor: 2.980

3.  Tocilizumab for the treatment of adult-onset Still's disease: results from a case series.

Authors:  Paola Cipriani; Piero Ruscitti; Francesco Carubbi; Ilenia Pantano; Vasiliki Liakouli; Onorina Berardicurti; Roberto Giacomelli
Journal:  Clin Rheumatol       Date:  2013-09-05       Impact factor: 2.980

4.  Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease.

Authors:  Taio Naniwa; Rei Ito; Maiko Watanabe; Yoshihito Hayami; Shinji Maeda; Kaneshige Sasaki; Shiho Iwagaitsu
Journal:  Clin Rheumatol       Date:  2010-09-15       Impact factor: 2.980

5.  Correlation of serum CX3CL1 level with disease activity in adult-onset Still's disease and significant involvement in hemophagocytic syndrome.

Authors:  Tsuyoshi Kasama; Hidekazu Furuya; Ryo Yanai; Kumiko Ohtsuka; Ryo Takahashi; Nobuyuki Yajima; Yusuke Miwa; Kazuo Kobayashi
Journal:  Clin Rheumatol       Date:  2012-02-10       Impact factor: 2.980

Review 6.  [Interleukin-6 inhibition as a potential therapeutic target in rheumatic diseases].

Authors:  C Iking-Konert; P Bartz-Bazzanella; D Falagan; M W Hofman; A Schwarting; T Dörner
Journal:  Z Rheumatol       Date:  2014-04       Impact factor: 1.372

7.  Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Authors:  Atsushi Ogata; Toshio Tanaka
Journal:  Int J Rheumatol       Date:  2012-01-18

Review 8.  Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.

Authors:  Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Int J Biol Sci       Date:  2012-10-24       Impact factor: 6.580

9.  Adult Onset Still's Disease and Autoinflammation.

Authors:  Petros Efthimiou; L Nandini Moorthy; Clio P Mavragani; Dimitris Skokos; Bruno Fautrel
Journal:  Int J Inflam       Date:  2012-08-29

10.  Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies.

Authors:  Clio P Mavragani; Evangelos G Spyridakis; Michael Koutsilieris
Journal:  Int J Inflam       Date:  2012-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.